Possible mechanisms behind taxane-anthracycline sequencing.

摘要

We read with great interest the comment by Wildiers and colleagues1 in the March, 2010, issue of The Lancet Oncology. The comment addresses the administration of a taxane first, followed by an anthracycline in the adjuvant or neoadjuvant clinical setting, and gives a different approach to choosing the best treatment options for early breast cancer. The authors discussed some of the rationale behind this approach, such as the relative drug-dose intensity achieved, skin toxicity, grade 4toxicity, pathological complete response rate, and the emergence of cross-resistance. However, the authors did not specifically mention proposals for the mechanism of this sequencing.